Development of a risk prediction model for vancomycin-associated acute kidney injury: a multicentre retrospective study
Journal of Antimicrobial Chemotherapy · 2026
DOI: 10.1093/jac/dkag012 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Tomoyuki Ishigo und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Sapporo Medical University Hospital, Sapporo, Japan. Hauptthemen laut MEDLINE: Acute Kidney Injury, Vancomycin, Anti-Bacterial Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
To clarify the relationship between acute kidney injury (AKI) and vancomycin use in patients with renal impairment and to establish a risk score for AKI.
Methods
In this retrospective, multicentre, observational cohort study, trough and peak blood samples were collected from patients who initiated vancomycin therapy. The cumulative incidence of AKI within 14 days was compared among three groups classified according to renal function (estimated glomerular filtration rate ≥ 60, 30–59 and <30 mL/min/1.73 m2). The risk score and predicted probability of AKI incidence were calculated. AKI was defined in accordance with the Kidney Disease Improving Global Outcomes criteria.
Results
The incidence of AKI was 11.7% (99/847). No statistically significant difference was detected in the cumulative incidence of AKI among the three groups (P = 0.103). Cox proportional hazard analysis showed that the use of tazobactam/piperacillin [HR: 3.3, 95% CI (2.18–4.99), 2 points], vasopressors/inotropes [HR: 3.0, 95% CI (2.02–4.51), 2 points] and area under the concentration-time curve (AUC) on Day 2 [500–600 µg·h/mL: HR, 2.4, 95% CI (1.50–3.89), 1 point; >600 µg·h/mL: HR, 4.4, 95% CI (2.62–7.37), 3 points] were significantly related to the development of AKI. The predicted probabilities of AKI incidence were <5% (low-risk), 5% to <20% (moderate-risk), 20% to <40% (high-risk) and 40% to 67% (very high-risk), with total points of 0, 1–2, 3–4 and ≥5, respectively.
Conclusions
A risk prediction model was developed for AKI based on AUC exposure and concomitant medications, and no difference in AKI risk was observed across renal function categories.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Sapporo Medical University Hospital, Sapporo, Japan.
- Laboratory of Clinical Pharmacokinetics, School of Pharmacy, Kitasato University, Sagamihara, Japan.
- Department of Pharmacy, Kitasato University Hospital, Sagamihara, Japan.
- Department of Pharmacy, Showa Medical University Hospital, Tokyo, Japan.
- Department of Pharmacy, Kyorin University Hospital, Mitaka, Japan.
- Department of Hospital Pharmaceutics, School of Pharmacy, Showa Medical University, Tokyo, Japan.
ORCID-Profile: Tomoyuki Ishigo, Fumihiro Yamaguchi, Masaru Samura, Yuki Igarashi, Yuki Enoki, Kazuaki Matsumoto
Zitieren
APA
Ishigo, T., Suzuki, A., Ibe, Y., Fujii, S., Fukudo, M., Yoshida, H., Tanaka, H., Fujihara, H., Yamaguchi, F., Ebihara, F., Maruyama, T., Yagi, Y., Hamada, Y., Samura, M., Nagumo, F., Komatsu, T., Tomizawa, A., Takuma, A., Chiba, H., …, & Matsumoto, K. (2026). Development of a risk prediction model for vancomycin-associated acute kidney injury: a multicentre retrospective study. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkag012
Vancouver
Ishigo T, Suzuki A, Ibe Y, Fujii S, Fukudo M, Yoshida H, et al. Development of a risk prediction model for vancomycin-associated acute kidney injury: a multicentre retrospective study. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkag012
BibTeX
@article{Ishigo2026,
author = {Ishigo, Tomoyuki and Suzuki, Ayako and Ibe, Yuta and Fujii, Satoshi and Fukudo, Masahide and Yoshida, Hiroaki and Tanaka, Hiroaki and Fujihara, Hisato and Yamaguchi, Fumihiro and Ebihara, Fumiya and Maruyama, Takumi and Yagi, Yusuke and Hamada, Yukihiro and Samura, Masaru and Nagumo, Fumio and Komatsu, Toshiaki and Tomizawa, Atsushi and Takuma, Akitoshi and Chiba, Hiroaki and Nishi, Yoshifumi and Igarashi, Yuki and Enoki, Yuki and Matsumoto, Kazuaki},
title = {Development of a risk prediction model for vancomycin-associated acute kidney injury: a multicentre retrospective study},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
doi = {10.1093/jac/dkag012}
}
EUVIMED